Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges.

Authors

Jordi Remon, Tina Cascone, Stephanie P L Saw, Nikolaj Frost, Molly S C Li, Lizza E L Hendriks, Antonin Levy, Alessandro Di Federico, Jamie E Chaft, Karim Abdelhamid, Mark Awad, Giannis Mountzios, Solange Peters

Published in

The Lancet. Respiratory medicine. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

The treatment of early-stage non-small-cell lung cancer (NSCLC) has evolved substantially in recent years. For decades, curative-intent surgery followed by platinum-based chemotherapy remained the standard of care (SOC), despite delivering only modest gains in long-term survival. Current evidence from randomised trials incorporating immunotherapy as a neoadjuvant or perioperative approach, along with targeted therapies, have defined a new SOC treatment approach for patients with resectable early-stage NSCLC. However, these advances have introduced uncertainties regarding optimal sequencing, treatment duration, patient selection, and the role of treatment escalation or de-intensification with immunotherapy and targeted therapies. The advances and uncertainties are discussed in this Series paper, along with the role of radiotherapy in this setting.

PMID:
42702210
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.